Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bio Bridge Science (CE) Charts. Click Here for more Bio Bridge Science (CE) Charts.](/p.php?pid=staticchart&s=NO%5EBGES&p=8&t=15)
Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of
vaccines with broad preventative and therapeutic applications, today
announced that it has completed the major construction of a new
state-of-the-art GMP research and manufacturing facility located in
Beijing. The facility will provide a high quality research and
production environment for the Company's vaccine products as well as
pre-clinical and clinical trials.
The first phase of the facility consists of an area 2,200 square
meters, which includes the main facility, where research and
production will take place. The research area consists of an 815
square meter clean air surface area. This area includes a 470 square
meter 100,000 purity grade clean air environment, and a 345 square
meter 10,000 purity grade clean air environment. There will also be
several 100 purity grade clean air environments within the 10,000
purity grade area. The facility also includes a 750 square meter
general working area and a 435 square meter electricity and water
area.
"We are pleased to have completed the initial stage of development
for this state-of-the-art facility," said Bio-Bridge Science's CEO Dr.
Liang Qiao. "This facility will allow us to produce the first HIV
Vaccine in China, develop additional vaccines to cervical and colon
cancers and to accelerate many of our promising research activities."
The interior and exterior construction was completed according to
GMP rules and requirements; however, construction of the high and low
voltage electricity and installation of steam equipment is still
taking place with local suppliers.
About Bio-Bridge Science:
Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine that is expected
to enter clinical trials this year in China. The vaccine, based on
exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV. The Chinese government, mindful of the rapid
expansion of AIDS in China has, through the "Green Mile Policy", acted
to expedite the approval of domestically produced HIV Vaccines.
Bio-Bridge Science's GMP facility will also be used to develop
vaccines against cervical cancer and colon cancer under the same
technology platform as the HIV vaccine.
Forward Looking Statements
This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in statements
filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition, the
company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
Please refer to SEC filings for additional information and
accompanying notes to financial statements.